Search News Archives
Special Offers and Promotions
Conferences | Events
HPLC Column Separates Wide Variety of Pharmaceutical Counterions
Thermo Fisher Scientific is pleased to announce the expansion of the Acclaim™ Trinity™ family of HPLC column with new Acclaim Trinity P2 columns.
The new columns are designed to screen a wide range of counterions, including cations, anions, mono and multi-valent ions with one analysis, thanks to advanced mixed-mode Nanopolymer Silica Hybrid (NSH™) technology. Simple LC screening of the Active Pharmaceutical Ingredients (API) and their counterions can be achieved with high sensitivity using the Thermo Scientific™ Dionex™ Corona™ Charged Aerosol Detector.
The chemistry is designed to provide spatial separation of the anion exchange and cation regions, resulting in greater resolution and selectivity control. Also, the particles’ hydrophilic surface makes the Acclaim Trinity P2 useful as a HILIC column. It provides cation exchange, anion exchange and HILIC retentions on the same stationery phase, helping customers develop robust, fast, generic methods to improve productivity and reduce cost.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. With revenues of $12 billion, we have approximately 39,000 employees and serve customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as in environmental and process control industries. We create value for our key stakeholders through three premier brands, Thermo Scientific, Fisher Scientific and Unity™ Lab Services, which offer a unique combination of innovative technologies, convenient purchasing options and a single solution for laboratory operations management. Our products and services help our customers solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity.